Abstract
Redirect the immune response by genetic modification of T-cells with chimeric antigen receptor (CAR) is an emerging immunotherapeutic approach for a variety of neoplastic diseases, including lymphomas and leukemias, reaching an impressive momentum with several ongoing clinical trials. Initial data indicate the need for a large number of cells (10-100 billion) to infuse into the patient be…